300639.SZ
Guangdong Hybribio Biotech Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 6.00
+6.95%Oct 21, 2026, 08:39 UTC
Kaipu Biotech completed its share repurchase, buying back 25.7103 million shares, or 3.98% of its total share capital, for a total of approximately RMB 150 million including transaction fees.
Source:Oct 11, 2026, 08:13 UTC
Chaozhou Hybribio Biochemistry Co., Ltd., a wholly owned subsidiary of Hybribio, obtained a Class III medical device registration certificate from China’s National Medical Products Administration for a vaginal microorganism nucleic acid detection kit.
Source:Sep 30, 2026, 08:40 UTC
Kangpu Biotech repurchased a cumulative 21.5736 million shares, or 3.34% of total share capital, for 125 million yuan under its buyback program as of September 30, 2026.
Source:Aug 31, 2026, 08:46 UTC
Hypro Biotechnology and its subsidiaries obtained a Chinese invention patent authorization for a sample tube fixing device and usage method in August 2026, which belongs to the in vitro diagnostic technology field.
Source:Jul 21, 2026, 10:22 UTC
Kaipu Bio's wholly-owned subsidiary Guangzhou Kaipu Medical Technology Co., Ltd. received a revised Medical Device Production License from the Guangdong Provincial Drug Administration, involving a change in production scope.
Source: